Command Palette

Search for a command to run...

Clinical Trials · NCT04641312

A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes

CompletedPhase 1Dulaglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
67
Start date
Nov 2020
Locations
2 sites, Germany
Primary endpoint
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
View Dulaglutide compound reference